论文部分内容阅读
ALL 是一种异质性疾病,需不同的治疗,标危组复发率为20～30%。6MP 至诱导和维持治疗中有重要作用。常用量100mg/m~2/d,分一或二次口服。按“越多越好”化疗原则,近来有加大剂量的研究。6MP 在体内经转化为活性形式,转化中有饱和现象,用6MP 血浆药动学指数指导临床用药作用有限。当血浆浓度达某一水平(未确定)时,转化减少,细胞毒减少,副作用增加。Ⅰ期试验中,50mg/m~2/小时,静脉注射,6MP 血浆稳态浓度为5～10μmol/L,CSF 中浓度为血浆的20～30%,有显著细胞毒作
ALL is a heterogeneous disease, requiring different treatment, the standard risk group relapse rate was 20 to 30%. 6MP to induce and maintain treatment has an important role. Commonly used amount of 100mg / m ~ 2 / d, divided into one or two oral. Press “as many as possible” chemotherapy principle, recently increased dose of research. 6MP is converted to an active form in vivo with saturation in the transformation and 6MP plasma pharmacokinetic index is used to guide the clinical use of the drug. When the plasma concentration reaches a certain level (not sure), the conversion decreased, cytotoxicity decreased, side effects increased. In phase I trial, 50 mg / m ~ 2 / h, intravenous injection, 6 MP plasma steady state concentration of 5 ~ 10μmol / L, CSF concentration of 20 ~ 30% of plasma, a significant cytotoxicity